27 October 2025   As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind .   The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor-immune microenvironment (TME) model

16 December 2025   Put in place to accelerate the development of innovative cancer therapies through collaboration initiatives, the Netherlands-based Oncode Accelerator program announces launching of its Demonstrator Project. Through this project, researchers and drug developers will be able to share expertise, experimental platforms, and infrastructure to advance novel therapeutic approaches.   Recent advances in cancer therapies and in particular immunotherapy have produce

26 September 2025   Inductive Bio , an AI drug discovery partner developing virtual chemistry labs, is awarded up to $21M by Advanced Research Projects Agency for Health (ARPA-H)  to develop AI-powered human-relevant drug toxicity prediction models. ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics  (CATALYST) program aims to revolutionize preclinical drug safety prediction by leveraging human-based models that assess safety of drug candidates more

18 November 2025   Emulate, Inc.  the pioneer of organ-on-a-chip technology, announces the launch of its Brain-Chip R1 platform, marketed as a first-in-class comprehensive model of the neurovascular unit. This latest organ-on-chip model provides the means for human-relevant drug discovery, assessment of drug transport across the blood-brain barrier (BBB), and investigation of mechanisms of neuroinflammation.   This is particularly important since human neurological diseases,

12 November 2025   Inventia Life Science's 3D bioprinted patient-derived cancer models has opened the door for Hunter Medical Research Institute to advance its drug repurposing program into Australian New Zealand clinical trials .   The drug in question, efavirenz, is known as an antiretroviral NNRTI (non‑nucleoside reverse transcriptase inhibitor) used for treating HIV. Its repurposing has the potential to improve the survival of patients with high-grade serous ovarian cance